NCT00352859 2014-12-30Phase IV Randomization to On-Going Treatment to Evaluate Sustained SorafenibBayerPhase 4 Terminated2 enrolled
NCT00117637 2014-10-31BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell CarcinomaBayerPhase 2 Completed189 enrolled 44 charts